 | WIN the Scope That's Winning Over Engineers.
Engineers all over are putting the Tektronix MDO4000 Mixed Domain Oscilloscope to the test. And you could be next. Enter now for a chance to win the world's first and only scope with a built-in spectrum analyzer. |
 | Ligand licenses oral lasofoxifene to Ethicor Pharma Ethicor Pharma secured rights to manufacture and distribute Ligand Pharmaceuticals' oral lasofoxifene for the Indian subcontinent, European Economic Area and Switzerland. Ethicor plans to distribute the drug, whose indications include osteoporosis, as an unlicensed medicinal product. The deal entitles Ligand to potential milestone fees and sales royalties. Genetic Engineering & Biotechnology News (7/24) Cepheid wins FDA nod for TB and rifampin-resistance test Cepheid has been cleared by the FDA to market its Xpert MTB/RIF assay, which is used to spot Mycobacterium tuberculosis complex DNA more quickly than existing methods. The test, which runs on the company's GeneXpert Systems, is also used to spot rpoB gene mutations linked to rifampin resistance in samples found to have MTB-complex DNA. RTT News (7/25) FDA puts Vertex's hepatitis C drug on partial clinical hold A midstage trial of Vertex Pharmaceuticals' investigational hepatitis C drug VX-135 was placed on partial clinical hold by the FDA. The move was made after three patients treated with 400 milligrams of the drug had elevated levels of liver enzymes. "We are committed to continuing to work closely with the FDA to provide the data needed to support evaluation of a 200 mg dose of VX-135 in the U.S.," said Chief Medical Officer Robert Kauffman of Vertex. Reuters (7/25) Biggest data set of cancer-related genes unveiled by scientists The National Cancer Institute has developed a database of cancer-related genetic variations for use by researchers. "To date, this is the largest database worldwide, containing 6 billion data points that connect drugs with genomic variants for the whole human genome across cell lines from nine tissues of origin, including breast, ovary, prostate, colon, lung, kidney, brain, blood, and skin," said Dr. Yves Pommier. The data set will be available through the CellMiner and Ingenuity portals. Oncology Nurse Advisor online (7/24)  | Getting Ready for the Physician Payment 'Sunshine' Rule
Get expert analysis and practical guidance to comply with the Physician Payment 'Sunshine' Rule, which mandates that certain manufacturers and group purchasing organizations (GPOs) report payments made to physicians, hospitals and other health-care providers.
Determine immediate action items for compliance with the rule—11 key suggested steps are outlined. Download Now. |
 | Stem cell-culturing company gets $2.3M boost StemBioSys secured $2.3 million and could bring in $5.6 million more in funding. Proceeds will be used for the expansion and development of its three-dimensional stem cell culture for use with cells from tissues such as bone marrow, umbilical cord blood and fat. MedCityNews.com (7/25) | Scientists ID gene that boosts oil palm production An international group of researchers sequenced the genome of the oil palm and found a gene that allows some trees to produce more oil than others. The data, published in the journal Nature, could pave the way for more sustainable agriculture. "We can now use that gene in genetic testing, which will allow breeders as well as producers to know exactly what sort of tree they are planting before it produces fruit," said Robert Martienssen of Cold Spring Harbor Laboratory. BBC (7/24)  | EvaluatePharma World Preview 2013, Outlook to 2018
In this sixth annual edition report, Evaluate brings together many of our analyses to provide top level insight into the expected performance of the industry between now and 2018. The report highlights trends in Rx drug sales, patent risk, R&D spend and sales by therapy area as well as a brief review of 2012 performance. Download your complimentary report now. |
 | | Industrial & Environmental | | Register today for the BIO Investor Forum, Oct. 8-9, in San Francisco The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One partnering meetings. BIO is renowned for its successful business development, partnering and investor meetings in North America, Europe and Asia. Partnering at this conference will be powered by BIO One-on-One Partnering, an interactive environment to intelligently search, contact and schedule private meetings with potential partners and investors. Register today. |  | People grow through experience if they meet life honestly and courageously." -- Eleanor Roosevelt, U.S. first lady | | | The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com. | Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
| Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | |
No comments:
Post a Comment